May 29th, 2022


Volume 55
Number 4
   
 Editorial
273
Lawrence D. Devoe, M.D.


 Symposium
 Gestational Trophoblastic Disease: Presentations from the XIVth World Congress on Gestational Trophoblastic Diseases. R. S. Berkowitz, Guest Editor
275
A. Folkins, M.D., L. Cruz, M.S., D. P. Goldstein, M.D., R. S. Berkowitz, M.D., C. Crum, M.D. and D. Kindelberger, M.D.
Chromogenic chromosomal in situ hybridization is comparable to flow cytometry and cytogenetics as an adjunctive technique to aid in the diagnosis of early hydatidiform moles.


279
W. B. Growdon, M.D., A. J. Wolfberg, M.D., M.P.H., D. P. Goldstein, M.D., C. M. Feltmate, M.D., M. E. Chinchilla, M.S., E. S. Lieberman, M.D., Dr.P.H. and R. S. Berkowitz, M.D.
This investigation sought to perform a 30-year retrospective review of methotrexate-resistant low-risk gestational trophoblasic neoplasia to determine if we could identify clinical factors that were associated with the need for multiagent chemotherapeutic regimens.


285
R. A. Harvey, B.Sc., Ph.D., H. D. C. Mitchell, B.Sc., U.-H. Stenman, M.D., Ph.D., M. A. Blankenstein, M.D., K. Nustad, M.D., Ph.D., P. Stieber, M.D., Ph.D., W. Stewart, B.Sc., Ph.D., P. M. Savage, FRCP, Ph.D., M. J. Seckl, FRCP, Ph.D. and G. D. Braunstein, M.D.
Most instructions accompanying over-the-counter ovulation prediction devices are presented with a reading difficulty level, text size, diagrams and instructions that make them suboptimal for patient education.


296
S. M. Patel, M.D., and A. Desai, M.D.
Sixteen cases of drug-resistant gestational trophoblastic neoplasia from July 2005 to June 2009 were studied retrospectively. Management and outcome are analyzed in this study.


301
J. M. Price, M.B.Ch.B, B. W. Hancock, M.D., J. Tidy, M.D., J. Everard, R.G.N., and R. E. Coleman, M.D.
We reviewed screening for central nervous system involvement, the frequency of cerebral metastases, and the impact of results on subsequent treatment to evaluate the Sheffield Trophoblastic Treatment Center protocol for central nervous system involvement in high-risk patients with gestational trophoblastic neoplasia.


305
P. D. P. B. Soares, M.D., I. Maestá, M.D., O. L. N. Costa, M.D., R. C. Charry, M.D., A. Dias, Ph.D., and M. V. C. Rudge, M.D.
Dramatically different incidence rates for gestational trophoblastic disease have been reported to occur not only between countries, but also within the same region.


311
I. Maestá, M.D., F. V. Leite, M.S.-V.I., O. C. Michelin, M.D., and S. R. Rogatto, Ph.D.
Although most commonly seen in patients with a previous history of molar pregnancy, primary pulmonary choriocarcinoma can also be found in patients with a history of term pregnancies, spontaneous and induced abortion, and ectopic pregnancy.


317
S. Sasaki, M.D., Ph.D., Y. Sasaki, M.D., Ph.D., and K. Iino, M.D., Ph.D.
After the establishment of real human chorionic gonadotropin and hyperglycosylated human chorionic gonadotropin, an accurate diagnosis of gestational trophoblastic disease should be obtained.


321
Ma. S. F. S. Cagayan, M.D., F.P.O.G.S., and R. T. Llarena, M.D.
Race or cultural diversity aside from factors such as age, baseline physiologic functioning, level of education and types of therapy used may affect results of quality of life studies among gestational trophoblastic neoplasia survivors.


327
Ma. S. F. S. Cagayan, M.D., F.P.O.G.S., and C. M. W. Oras, M.D.
There is a significant use of complementary and alternative medicine modalities among women with gestational trophoblastic disease at Philippine General Hospital; physicians should routinely ask and discuss this with their patients.


333
A. Chauhan, M.D., K. Dave, M.D., A. Desai, M.D., M. Mankad, M.D., S. Patel, M.D., and P. Dave, M.D.
High-risk gestational trophoblastic neoplasia requires aggressive multimodal treatment and should be managed at the institutional level.


341
P. Savage, Ph.D., FRCP, J. Williams, B.Sc., MRCP, S.-L. Wong, B.Sc., MRCP, D. Short, S. Casalboni, K. Catalano and M. Seckl, Ph.D., FRCP
The most significant documented variable for the occurrence of a molar pregnancy is the maternal age at the time of conception.


 Original Articles
346
Y. J. M. Ioffe, M.D., R. G. Elmore, M.D., B. Y. Karlan, M.D., and A. J. Li, M.D.
We found that smoking at the time of initial cytoreductive surgery is associated with poorer progression-free and overall survival.


351
J. S. Carter, M.D., Y. Hoffman Sage, M.D., M.P.H., O. Vragovic, M.B.A., L. Rosen, M.S.E.E., and E. A. Stier, M.D.
Women with minimally abnormal Pap tests have poor compliance; those who undergo colposcopic evaluation have similar risks for CIN2 and CIN3 regardless of age.


357
R. W. Driggers, M.D., R. J. Chason, M.D., C. Olsen, Dr.P.H., and C. M. Zahn, M.D.
There is no significant difference in scores from residents working on a daytime schedule vs. a night float schedule before administration of the in-service examination.


 Case Reports
362
C. E. Henderson, M.D., C.D.E., R. G. Hana, M.D., R. Woroch, M.D., and K. D. Reilly, M.D.
Short interconception interval and misoprostol used as a uterotonic agent may be additive risks for uterine rupture.


 

The opinions and statements in this journal are those of the authors and are not attributable to the sponsor, publisher, editors or editorial board of JRM. Product dosages, indications and methods of use referred to in the papers and discussions reflect the authors' clinical experience or are derived from other professional sources.